Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Appoints New Board Member and Announces Departure of Director
Summary
On February 23, 2024, Jazz Pharmaceuticals plc appointed Patrick Kennedy to its Board as a Class I director, effective March 1, 2024. Kennedy, who will also serve on the Audit Committee, will receive compensation in line with the company's standard arrangements for non-employee directors. Concurrently, Peter Gray notified the Board of his decision not to stand for re-election at the 2024 Annual Meeting, a decision made without any dispute with the Company.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement